Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.22.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 8,138 $ 6,037
Restricted cash 211 295
Receivables 218 112
Inventory 293 293
Prepaid expenses and other current assets 749 480
Discontinued operations - current assets 24 12
Total current assets 9,633 7,229
Property and equipment, net 368 420
Other assets 48 48
Operating lease right-of-use asset 269 297
Total assets 10,318 7,994
Current liabilities:    
Accounts payable 468 795
Accrued clinical trials expenses 39 9
Other accrued liabilities 320 314
Operating lease liability, current 114 112
Deferred grant revenue 211 295
Discontinued operations - current liabilities 1,126 1,144
Total current liabilities 2,278 2,669
Operating lease liability, non-current 158 187
Total liabilities 2,436 2,856
Stockholders' equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 12,039,421 and 9,914,158 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively. 12 10
Additional paid-in capital 386,465 381,183
Accumulated deficit (378,595) (376,055)
Total stockholders' equity 7,882 5,138
Total liabilities and stockholders' equity $ 10,318 $ 7,994